These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20869706)

  • 1. Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up.
    von Wolff M; Kämmerer U; Kollmann Z; Santi A; Dietl J; Frambach T
    Fertil Steril; 2011 Jan; 95(1):452-4. PubMed ID: 20869706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of gonadotropin releasing hormone analogues on chemotherapy-induced ovarian function damage in rats].
    Peng P; Yang DZ; Zheng CY; Mo YQ; He YM; Zhang QX
    Zhonghua Fu Chan Ke Za Zhi; 2007 Aug; 42(8):546-50. PubMed ID: 17983495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
    De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
    Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot study.
    Mueller A; Maltaris T; Häberle L; Hoffmann I; Beckmann MW; Dittrich R
    Fertil Steril; 2009 Feb; 91(2):647-8. PubMed ID: 18423456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development.
    Chung K; Fogle R; Bendikson K; Christenson K; Paulson R
    Fertil Steril; 2011 Jan; 95(1):317-9. PubMed ID: 20813363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
    Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
    Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of ovarian function and fertility using a combination of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females.
    Potolog-Nahari C; Fishman A; Cohen I
    Gynecol Endocrinol; 2007 May; 23(5):290-4. PubMed ID: 17558688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists.
    Bedaiwy MA; Mousa NA; Casper RF
    Fertil Steril; 2009 Apr; 91(4 Suppl):1574-7. PubMed ID: 18973892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gonadotropin releasing hormone (GnRH) antagonists--a new provocation in gynecology].
    Vladimirov Ia
    Akush Ginekol (Sofiia); 2002; 41(3):36-42. PubMed ID: 12145978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in vitro fertilization outcome.
    Rabinson J; Meltcer S; Zohav E; Gemer O; Anteby EY; Orvieto R
    Fertil Steril; 2008 Feb; 89(2):472-4. PubMed ID: 17582402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and late hormonal responses to the microdose gonadotropin-releasing hormone agonist in normal menstruating women.
    Park WI; Kim SS; Chung HR; Shin SY; Lee JY
    Fertil Steril; 2004 Apr; 81(4):1067-72. PubMed ID: 15066465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study.
    Li X; Kang X; Deng Q; Cai J; Wang Z
    Reprod Biol Endocrinol; 2013 Mar; 11():16. PubMed ID: 23452939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues?
    Orvieto R; Meltzer S; Rabinson J; Gemer O; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1297-300. PubMed ID: 18249369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.
    Beck-Fruchter R; Weiss A; Shalev E
    Hum Reprod Update; 2008; 14(6):553-61. PubMed ID: 18820006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome.
    Bosch E; Escudero E; Crespo J; Simón C; Remohí J; Pellicer A
    Fertil Steril; 2005 Nov; 84(5):1529-32. PubMed ID: 16275263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.